BR112022018682A2 - Anticorpos anti-ceramida - Google Patents

Anticorpos anti-ceramida

Info

Publication number
BR112022018682A2
BR112022018682A2 BR112022018682A BR112022018682A BR112022018682A2 BR 112022018682 A2 BR112022018682 A2 BR 112022018682A2 BR 112022018682 A BR112022018682 A BR 112022018682A BR 112022018682 A BR112022018682 A BR 112022018682A BR 112022018682 A2 BR112022018682 A2 BR 112022018682A2
Authority
BR
Brazil
Prior art keywords
antibodies
individual
ceramid
antigen
need
Prior art date
Application number
BR112022018682A
Other languages
English (en)
Inventor
Kolesnick Richard
Tinkelenberg Arthur
Kuo-Ming Wang Jordon
Wu Yinan
Wang Yong
Levy Raphael
Original Assignee
Memorial Sloan Kettering Cancer Center
Ceram Holding Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center, Ceram Holding Llc filed Critical Memorial Sloan Kettering Cancer Center
Publication of BR112022018682A2 publication Critical patent/BR112022018682A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

ANTICORPOS ANTI-CERAMIDA. A presente divulgação fornece composições de anticorpos anti-ceramida e fragmentos de ligação ao antígeno dos mesmos. A divulgação fornece ainda métodos para prevenir ou inibir a morte celular em um indivíduo em necessidade do mesmo, compreendendo administrar os anticorpos anti-ceramida ou fragmentos de ligação ao antígeno a um indivíduo. O indivíduo em necessidade pode sofrer de uma doença autoimune, síndrome GI ou GvHD.
BR112022018682A 2020-03-18 2021-03-18 Anticorpos anti-ceramida BR112022018682A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062991232P 2020-03-18 2020-03-18
PCT/US2021/022914 WO2021188770A1 (en) 2020-03-18 2021-03-18 Anti-ceramide antibodies

Publications (1)

Publication Number Publication Date
BR112022018682A2 true BR112022018682A2 (pt) 2023-02-14

Family

ID=77771401

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022018682A BR112022018682A2 (pt) 2020-03-18 2021-03-18 Anticorpos anti-ceramida

Country Status (11)

Country Link
US (1) US20230167197A1 (pt)
EP (1) EP4121110A1 (pt)
JP (1) JP2023534779A (pt)
KR (1) KR20230031814A (pt)
CN (1) CN115811987A (pt)
AU (1) AU2021236669A1 (pt)
BR (1) BR112022018682A2 (pt)
CA (1) CA3172201A1 (pt)
IL (1) IL296550A (pt)
MX (1) MX2022011591A (pt)
WO (1) WO2021188770A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017002433A2 (pt) 2014-08-07 2017-11-28 Ceram Therapeutics anticorpos anticeramida

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110043786A (ko) * 2008-08-20 2011-04-27 센토코 오르토 바이오테크 인코포레이티드 조작된 항-ｉｌ-13 항체, 조성물, 방법 및 용도
BR112017002433A2 (pt) * 2014-08-07 2017-11-28 Ceram Therapeutics anticorpos anticeramida

Also Published As

Publication number Publication date
CN115811987A (zh) 2023-03-17
IL296550A (en) 2022-11-01
US20230167197A1 (en) 2023-06-01
CA3172201A1 (en) 2021-09-23
JP2023534779A (ja) 2023-08-14
MX2022011591A (es) 2023-03-06
AU2021236669A1 (en) 2022-11-10
KR20230031814A (ko) 2023-03-07
EP4121110A1 (en) 2023-01-25
WO2021188770A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
Cardoso et al. Short‐and long‐term mortality after bariatric surgery: a systematic review and meta‐analysis
CL2019003728A1 (es) Moléculas de unión a antígeno que comprenden un trímero de ligando de la familia de tnf. (divisional solicitud 201701000)
BR112022017986A2 (pt) Anticorpos anticoronavírus e métodos de uso
BR112016003369A2 (pt) diacorpos monovalentes biespecíficos, diacorpos fc monovalentes biespecíficos, composição farmacêutica, uso da composição farmacêutica, célula que expressa uma cadeia de polipeptídeo de quaisquer dos diacorpos monovalentes biespecíficos, polinucleotídeo que codifica o polipeptídeo, e célula que expressa um anticorpo ou uma porção de polipeptídeo ou fragmento da mesma
BRPI0812913A8 (pt) Anticorpos monoclonais ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotideo, método para produzir os referidos anticorpos ou fragmentos de anticorpos, composição que os compreende e uso dos mesmos
BR112016011401A2 (pt) moduladores de aplnr e utilizações dos mesmos
BR112016030686A2 (pt) anticorpos anti tau humanizados
BR112012007365A2 (pt) proteínas de ligação à il-1
NO20080487L (no) Rekominant interferona2 (IFNa2) mutanter
Cox et al. Cadmium attenuates the macrophage response to LPS through inhibition of the NF-κB pathway
Valent Risk factors and management of severe life‐threatening anaphylaxis in patients with clonal mast cell disorders
BR112020015915A8 (pt) Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer
BR112022003147A2 (pt) Novos anticorpos anti-cldn18.2
BR112013008407A2 (pt) antígenos de clostridium difficile
BR112022000328A2 (pt) Inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias
EA201991511A1 (ru) Кристаллическая структура гремлин-1 и ингибирующее антитело
WO2019028182A3 (en) TREATMENT OF CANCER USING ANTIBODIES BINDING TO THE HUMAN CD134 RECEPTOR (OX40)
BR112022003335A2 (pt) Conjugados de il-2 e métodos de uso para tratar doenças autoimunes
BR112021026133A2 (pt) Anticorpo anti-cd24 e usos do mesmo
BR112022021690A2 (pt) Anticorpos de cadeia pesada multispecíficos com regiões constantes de cadeia pesada modificadas
Yu et al. Curcumin attenuates inflammation in a severe acute pancreatitis animal model by regulating TRAF1/ASK1 signaling
BR112022018682A2 (pt) Anticorpos anti-ceramida
BR112021025077A2 (pt) Anticorpos anti-sortilina para uso em terapia
BR112021016791A2 (pt) Proteínas de ligação de antígenos que se ligam a bcma
Barbier et al. Endogenous interleukin-33 acts as an alarmin in liver ischemia-reperfusion and is associated with injury after human liver transplantation